Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8180111 | 0.78 | ALDH1A1 (0.42) | LMNASLC2A1KDM4ETDP1KMT2A | |
| SCHEMBL6773271 | 0.73 | KMT2A (0.34) | LMNAHTTSLC2A1KDM4ETDP1 | |
| SCHEMBL6963178 | 0.70 | KMT2A (0.34) | LMNAHTTSLC2A1KDM4ETDP1 | |
| SCHEMBL28005270 | 0.69 | MAPT (0.45) | SLC2A1KDM4ETDP1KMT2AL3MBTL1 | |
| SCHEMBL5076504 | 0.69 | — | — | |
| SCHEMBL347685 | 0.67 | TDP1 (0.50) | LMNATDP1KMT2AL3MBTL1IDO1 | |
| SCHEMBL14182015 | 0.67 | NPSR1 (0.38) | LMNAHTTKDM4ETDP1KMT2A | |
| SCHEMBL27928253 | 0.66 | TDP1 (0.48) | LMNATDP1KMT2AL3MBTL1IDO1 | |
| Hydrochloric Acid SCHEMBL29730240 | 0.66 | TDP1 (0.48) | LMNATDP1KMT2AL3MBTL1IDO1 | |
| Ammonia Solution, Strong SCHEMBL27928251 | 0.66 | TDP1 (0.48) | LMNATDP1KMT2AL3MBTL1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043994-A1 | Gem-substituted alpha v beta 3 antagonists | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | disclosed |
| EP-1313705-A1 | GEM-SUBSTITUTED ALPHA V BETA 3 INTEGRIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6531494-B1 | Gem-substituted αvβ3 antagonists | PHARMACIA CORPORATION | 2003-03-11 | — | — | US | disclosed |
| WO-2002018340-A1 | GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043994-A1 | Gem-substituted alpha v beta 3 antagonists | CACNG5, ITGAV, ITGA5 | LMNA 1617/4885HTT 4293/4885SLC2A1 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.